Spero Therapeutics (NASDAQ:SPRO) Posts Quarterly Earnings Results, Misses Estimates By $0.29 EPS

Spero Therapeutics (NASDAQ:SPRO) announced its earnings results on Thursday. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.29), FiscalAI reports. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%.

Spero Therapeutics Trading Down 2.0%

NASDAQ SPRO traded down $0.02 during mid-day trading on Thursday, reaching $1.00. 328,412 shares of the company’s stock traded hands, compared to its average volume of 777,181. Spero Therapeutics has a 1-year low of $0.96 and a 1-year high of $3.08. The company has a fifty day simple moving average of $1.15 and a 200-day simple moving average of $1.93. The company has a market cap of $58.24 million, a price-to-earnings ratio of 9.09 and a beta of 1.59.

Analyst Ratings Changes

A number of research firms recently weighed in on SPRO. Cantor Fitzgerald began coverage on shares of Spero Therapeutics in a report on Wednesday, October 28th. They set an “overweight” rating and a $6.00 price target for the company. Zacks Research upgraded shares of Spero Therapeutics to a “hold” rating in a report on Monday, September 14th. Compass Point upgraded shares of Spero Therapeutics to a “neutral” rating in a report on Monday, September 14th. Wall Street Zen cut shares of Spero Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Finally, HC Wainwright upped their price objective on shares of Spero Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Monday, September 14th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $6.00.

Insider Activity

In other Spero Therapeutics news, insider Esther Rajavelu sold 40,851 shares of the company’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $1.04, for a total value of $42,485.04. Following the transaction, the insider directly owned 946,000 shares of the company’s stock, valued at $983,840. This represents a 4.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.90% of the stock is currently owned by insiders.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc. (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens. Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.